Compass Therapeutics Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has a clinical trial catalyst to watch this quarter.
The company's lead drug candidate is Tovecimig (formerly CTX-009), a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A (VEGF-A) signaling pathways. Both of these are critical to angiogenesis and tumor vascularization.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.